Search results for "moda"

showing 10 items of 1753 documents

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment

2003

The effects of combined and simultaneously applied localised 43 degrees C hyperthermia (HT) and an antivascular bacteriochlorophyll-serine-based photodynamic therapy (Bchl-ser-PDT) on tumour growth and several microenvironmental parameters were examined. Rats bearing DS-sarcomas were allocated to treatment groups: (i) sham-treatment (control), (ii) Bchl-ser-PDT (20 mg kg(-1) i.v.), (iii) localised HT, (iv) Bchl-ser-PDT+HT. The light source used was an infrared-A irradiator, which, by use of appropriate filters, delivered the different ranges of wavelengths required. Following treatment, tumour volume was monitored. The greatest tumour growth inhibition was seen with Bchl-ser-PDT+HT, and sub…

MaleHyperthermiaCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentAngiogenesis InhibitorsPhotodynamic therapyOxidative phosphorylationBiologyPharmacologyRats Sprague-DawleyNeovascularizationchemistry.chemical_compoundmedicineAnimalsblood flowCombined Modality TherapyGlycolysisExperimental TherapeuticBacteriochlorophyllsPhotosensitizing AgentsNeovascularization PathologicbacteriochlorophyllHyperthermia InducedOxygenationhyperthermiamedicine.diseaseCombined Modality TherapyCell Hypoxiametabolic statusRatsPhotochemotherapyphotodynamic therapyOncologychemistryModels AnimalSarcoma ExperimentaloxygenationGrowth inhibitionmedicine.symptomCell DivisionBritish Journal of Cancer
researchProduct

Hot Topic Water-filtered infrared-A radiation: a novel technique for localized hyperthermia in combination with bacteriochlorophyll-based photodynami…

1999

A novel application of an infrared-A (IR-A) radiation source equipped with a water-filter in the radiation path is described, which allows for tumour treatment with a simultaneous combination of localized hyperthermia (HT) and bacteriochlorophyll-serine (Bchl-ser) based photodynamic therapy (PDT). Using this system, the IR-A radiation was used to heat tumours to 43 degrees C for 60 min, while at the same time activating the Bchl-ser which was injected i.v. at a dose of 20 mg/kg, 10 min following commencement of HT. The growth of tumours undergoing this combined therapy was compared to that of tumours undergoing HT alone or sham-treated controls. Within the 90 day observation period, 100% of…

MaleHyperthermiaNovel techniqueCancer ResearchInfrared RaysPhysiologymedicine.medical_treatmentPlanning target volumePhotodynamic therapyRadiationRats Sprague-Dawleychemistry.chemical_compoundPhysiology (medical)medicineAnimalsBacteriochlorophyllsbusiness.industryWaterHyperthermia InducedNeoplasms Experimentalmedicine.diseaseCombined Modality TherapyRatsPhotochemotherapychemistryCombined therapyBacteriochlorophyllGrowth inhibitionNuclear medicinebusinessInternational Journal of Hyperthermia
researchProduct

Erythropoietin neuroprotection is enhanced by direct cortical application following subdural blood evacuation in a rat model of acute subdural hemato…

2013

Recombinant human erythropoietin (EPO) has been successfully tested as neuroprotectant in brain injury models. The first large clinical trial with stroke patients, however, revealed negative results. Reasons are manifold and may include side-effects such as thrombotic complications or interactions with other medication, EPO concentration, penetration of the blood-brain-barrier and/or route of application. The latter is restricted to systemic application. Here we hypothesize that EPO is neuroprotective in a rat model of acute subdural hemorrhage (ASDH) and that direct cortical application is a feasible route of application in this injury type. The subdural hematoma was surgically evacuated a…

MaleIntracranial PressureLesionRats Sprague-DawleyHematomamedicineAnimalsHematoma Subdural AcuteErythropoietinIntracranial pressureCerebral Cortexbusiness.industryGeneral NeuroscienceSubdural hemorrhageVenous bloodmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalNeuroprotective AgentsCerebral blood flowBlood chemistryErythropoietinAnesthesiamedicine.symptombusinessmedicine.drugNeuroscience
researchProduct

Preoperative pain neuroscience education combined with knee joint mobilization for knee osteoarthritis : a randomized controlled trial

2017

Abstract: Objectives: This study aimed to first compare the effects of a preoperative treatment combining pain neuroscience education (PNE) with knee joint mobilization versus biomedical education with knee joint mobilization on central sensitization (CS) in patients with knee osteoarthritis, both before and after surgery. Second, we wanted to compare the effects of both interventions on knee pain, disability, and psychosocial variables. Materials and Methods: Forty-four patients with knee osteoarthritis were allocated to receive 4 sessions of either PNE combined with knee joint mobilization or biomedical education with knee joint mobilization before surgery. All participants completed self…

MaleKnee JointPsychological interventionOsteoarthritisKnee Jointlaw.inventionDisability Evaluation0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareMedicinephysical therapyPain MeasurementAged 80 and overMobilizationCatastrophizationMiddle AgedOsteoarthritis Kneemusculoskeletal systemPhobic DisordersManipulation OrthopedicFemalePain catastrophizingmedicine.symptomPsychosocialmusculoskeletal diseasesmedicine.medical_specialtyClinical NeurologyPaincentral sensitization syndromesknee osteoarthritisEducation03 medical and health sciencesDouble-Blind MethodPreoperative CareHumansPhysical Therapy ModalitiesAged030203 arthritis & rheumatologyAnalysis of Variancebusiness.industryNeurosciencesmedicine.diseaseAnesthesiology and Pain MedicineKnee painPhysical therapyNeurology (clinical)Human medicinebusinessNeuroscience030217 neurology & neurosurgeryThe clinical journal of pain
researchProduct

An easy and safe training method for trunk function improves mobility in total knee arthroplasty patients: A quasi-randomized controlled trial

2018

Objective Total knee arthroplasty (TKA) is aimed mainly at reducing pain and restoring mobility. However, mobility deficits can persist even longer than 1 year. The trunk function and movement velocity of any region have been recently recognized to be critical for determining mobility in older people. Therefore, the main goal of this quasi-randomized trial is to clarify the effectiveness of a novel training method, the seated side tapping (SST) training, for improving mobility by focusing on movement velocity of trunk function in the short term after TKA. Methods SST training consists of side trunk movements repeated as quickly as possible in a seated position. All participants after TKA we…

MaleKnee JointTotal Knee ArthroplastyPhysiologyKneesmedicine.medical_treatmentlcsh:MedicineWalkingKnee JointsTimed Up and Go testlaw.inventionElderly0302 clinical medicineSkeletal JointsRandomized controlled triallawMedicine and Health SciencesPublic and Occupational HealthProspective StudiesRange of Motion ArticularArthroplasty Replacement Kneelcsh:ScienceMusculoskeletal SystemPostural BalanceAged 80 and overMultidisciplinaryRehabilitationMiddle AgedOsteoarthritis KneeSports ScienceTreatment OutcomeTime and Motion StudiesStrength TrainingLegsFemaleAnatomy0305 other medical scienceRange of motionResearch Articlemedicine.medical_specialtyStrength trainingSurgical and Invasive Medical ProceduresArthroplasty03 medical and health sciencesMusculoskeletal System ProceduresPhysical medicine and rehabilitation030502 gerontologymedicineHumansSports and Exercise MedicineExercisePhysical Therapy ModalitiesAgedBiological Locomotionbusiness.industrylcsh:RBiology and Life SciencesPhysical ActivityArthroplastyTrunkWalking SpeedPreferred walking speedAge GroupsPhysical FitnessBody LimbsPeople and PlacesPopulation Groupingslcsh:Qbusiness030217 neurology & neurosurgeryPLOS ONE
researchProduct

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

2014

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated wi…

MaleMESH: Combined Modality TherapyAnal Carcinomamedicine.medical_treatmentMESH: Lymphatic MetastasisMedical OncologyMESH: Anus Neoplasms0302 clinical medicineDiagnosisSocieties MedicalMESH: Medical Oncologyeducation.field_of_studyIncidence (epidemiology)Follow-upAnal MarginMESH: Carcinoma Squamous CellGeneral MedicineHematologyMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisCombined Modality Therapy3. Good healthmedicine.anatomical_structureOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleRadiologymedicine.medical_specialtyHealth Planning GuidelinesPopulationMESH: Societies MedicalRectumGuidelinesMESH: Prognosis03 medical and health sciencesmedicineAnal cancerHumansRadiology Nuclear Medicine and imagingeducationNeoplasm StagingMESH: Humansbusiness.industryCancerAnusmedicine.diseaseMESH: MaleSurgeryRadiation therapyTreatmentSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieAnal cancerbusinessMESH: FemaleFollow-Up Studies
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct

Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections

2013

The type of surgery (radical pleurectomy (RP) vs. extrapleural pneumonectomy (EPP)) remains controversial for malignant pleural mesothelioma (MPM). Macroscopic complete resection (MCR) is a key prognostic factor. It is unclear, if patients undergoing incomplete RP within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP could theoretically have avoided incomplete resections (R2).Eighty-eight patients underwent RP followed by chemoradiation from 2002 to 2011 within a prospective multimodality treatment study at a single institution. MCR were compared to R2 within this patient cohort retrospectively. EPP eligibility was assessed retrospectivel…

MaleMesotheliomaPulmonary and Respiratory MedicineExtrapleural PneumonectomyCancer Researchmedicine.medical_specialtyPrognostic factorLung NeoplasmsPleural NeoplasmsKaplan-Meier EstimateDisease-Free SurvivalmedicineHumansProspective StudiesStage (cooking)PneumonectomyAgedRetrospective StudiesProportional hazards modelPleural mesotheliomabusiness.industryMultimodality TreatmentMesothelioma MalignantChemoradiotherapyThoracic Surgical ProceduresCombined Modality TherapySurvival AnalysisSurgeryTreatment OutcomeOncologyCohortFemalebusinessPleurectomyhormones hormone substitutes and hormone antagonistsLung Cancer
researchProduct

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

2008

Summary We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4 weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNγ, anti-α crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytoki…

MaleMicrobiology (medical)TuberculosisTuberculosiAntibodiemedicine.medical_treatmentImmunologyAntitubercular AgentsColony Count MicrobialMicrobiologyAntibodiesMycobacterium tuberculosisInterferon-gammaMiceAdjuvants ImmunologicRecurrencemedicineAnimalsalpha-CrystallinsRelapseTuberculosis PulmonaryCytokineMice Inbred BALB CMice Inbred C3HChemotherapyLungbiologybusiness.industryTuberculosis; Cytokines; Antibodies; Immunotherapy; RelapseIsoniazidMycobacterium tuberculosisImmunotherapybiology.organism_classificationmedicine.diseaseCombined Modality TherapyRecombinant ProteinsImmunoglobulin AMice Inbred C57BLRegimenInfectious Diseasesmedicine.anatomical_structureModels AnimalImmunologyInterleukin-4ImmunotherapybusinessRifampicinmedicine.drugTuberculosis
researchProduct